Concepedia

Author

Hiep Khong

The University of Texas MD Anderson Cancer CenterORCID

Also Known As

Faisal Fa’ak, H Khong, Hiep Khong

27

Publications

1.5K

Citations

12

H-Index

19

Concepts

All Affiliations

The University of Texas MD Anderson Cancer CenterThe University of Texas Health Science Center at HoustonUniversity of HoustonNational Institute Of Hygiene And Epidemiology
HK

About

Hiep Khong is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, autoimmunity, and immunology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

2

2

659

2

Cell Biology

2

2

659

3

Immunology

2

2

659

4

Autoimmunity

2

2

659

5

Autoimmune Disease

1

1

499

Hiep Khong

×

11

Publications

1.2K

Citations

10

H-Index

YearCitations

Genome-wide analysis identifies NR4A1 as a key mediator of T cell dysfunction

Xindong Liu, Yun Wang, Huiping Lu,

Nature

2019

499

Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy

Meenu Sharma, Hiep Khong, Faisal Fa’ak,

Nature Communications

2020

163

Effective Innate and Adaptive Antimelanoma Immunity through Localized TLR7/8 Activation

Manisha Singh, Hiep Khong, Zhimin Dai,

The Journal of Immunology

2014

160

HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes

Rina M. Mbofung, Jodi A. McKenzie, Shruti Malu,

Nature Communications

2017

148

Intratumoral CD40 activation and checkpoint blockade induces T cell-mediated eradication of melanoma in the brain

Manisha Singh, Christina Vianden, Mark J. Cantwell,

Nature Communications

2017

82

Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy

Yared Hailemichael, Amber N. Woods, Tihui Fu,

Journal of Clinical Investigation

2018

80

Fucosylation Enhances the Efficacy of Adoptively Transferred Antigen-Specific Cytotoxic T Lymphocytes

Gheath Alatrash, Na Qiao, Mao Zhang,

Clinical Cancer Research

2019

38

Preclinical Immune Response and Safety Evaluation of the Protein Subunit Vaccine Nanocovax for COVID-19

Thi Nhu Mai Tran, Bruce May, Trong Thuan Ung,

Frontiers in Immunology

2021

25

Safety and immunogenicity of Nanocovax, a SARS-CoV-2 recombinant spike protein vaccine: Interim results of a double-blind, randomised controlled phase 1 and 2 trial

Thuy Phuong Nguyen, Quyết Đỗ, Phan Trong Lan,

The Lancet Regional Health - Western Pacific

2022

23

Peptide Vaccine Formulation Controls the Duration of Antigen Presentation and Magnitude of Tumor-Specific CD8+ T Cell Response

Hiep Khong, Annika Volmari, Meenu Sharma,

The Journal of Immunology

2018

18

Page 1